Capital Wealth Alliance’s Novartis NVS Stock Holding History

Capital Wealth Alliance’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-30	Closed	-$3K	–	252
2019 Q4	$3K	Buy	+30	New	+$2.69K	﹤0.01%	285

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Wealth Alliance's NVS Position: Q1 2020 in Review

Capital Wealth Alliance sold out of Novartis (NVS) in Q1 2020, closing a stake of 30 shares — an estimated $3K sold.

Capital Wealth Alliance first reported a position in NVS in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 1,133 funds tracked by Wall St. Rank hold NVS as of Q1 2020.

Capital Wealth Alliance reported no remaining Novartis position as of Q1 2020 after selling out during the quarter.
Capital Wealth Alliance sold 30 Novartis shares in Q1 2020, an estimated $3K.
Capital Wealth Alliance first reported a position in Novartis in Q4 2019 and held it in 1 quarter.
Capital Wealth Alliance's Novartis position peaked at $3K in Q4 2019.
1,133 funds tracked by Wall St. Rank held Novartis as of Q1 2020.

Based on Capital Wealth Alliance's 13F filing for Q1 2020, filed 28 Apr 2020.